Sanara MedTech price target raised to $53 from $51 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Sanara MedTech (SMTI) to $53 from $51 and keeps a Buy rating on the shares following the Q1 report. The firm believes Sanara Surgical segment could continue to drive sales growth as the company increases regional sales managers and territories and grows distribution partners.